TRADITIONAL 3-DOSE VACCINES

TRADITIONAL 3-DOSE HEPATITIS B VACCINES MAY CREATE

A FALSE SENSE OF SECURITY

The majority of people who do not receive all 3 doses of traditional hepatitis B vaccines fail to achieve protective immunity.1

Hand with Surgical Instruments

You only achieve protective immunity when your anti-HBs threshold is ≥10 mIU/mL.2

Arrow Graph Arrow Graph

Abbreviation: Anti-HBs, antibody against hepatitis B surface antigen.

TRADITIONAL 3-DOSE HEPATITIS B VACCINES HAVE PROVEN TO BE DIFFICULT TO COMPLETE

~40%

of HCPs did not receive all 3 doses3

~75%

of adults aged 19+ did not receive all 3 doses4


EVEN AFTER COMPLETING ALL 3 DOSES OF A TRADITIONAL HEPATITIS B VACCINE, MANY FAIL TO ACHIEVE PROTECTIVE IMMUNITY

20-30%

~20% to 30% of people failed to achieve protective immunity and remain unprotected5

~35%

~35% of people with diabetes failed to achieve protective immunity and remain unprotected5,6


IT TAKES 6 MONTHS TO COMPLETE A TRADITIONAL 3-DOSE HEPATITIS B VACCINE SERIES1

Risk of HBV Infection Chart
96% Chart 73% Chart 18.7% Chart

The risk of infection remains

For most people until after the third dose is completed1

Video Thumbnail

The limitations of 3-dose vaccines

Dr. Robert Gish talks about the limitations of traditional 3-dose hepatitis B vaccines.

Watch full video
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Please see full Prescribing Information.

Phone IconCall 1-84-HEPLISAV (1-844-375-4728) or order online.
Call to Order
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Please see full Prescribing Information.

References:

1. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33. 2. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67(1):1-31. 3. Immunization and Infectious Diseases. Office of Disease Prevention and Health Promotion website. https://www.healthypeople.gov/2020/data-search/Search-the-Data#objid=4677. Accessed January 7, 2019. 4. Williams WW, Lu PJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ. 2017;66(11):1-28. 5. HEPLISAV-B [package insert]. Berkeley, CA: Dynavax Technologies Corporation; 2018. 6. Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018;36(5):668-674. 7. Dynavax Technologies Corporation. FDA Advisory Committee briefing document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD.